HIV

Causes of death among sub-Saharan African infants living with HIV and hospitalised with severe pneumonia, using minimally invasive autopsies in the EMPIRICAL trial

2025

Authors: Moraleda C, Madrid L, Rakislova N, Buck WC, Sacarlal J, Chabala C, Hurtado JC, Cassia U, Domínguez-Rodríguez S, Carrilho C, Varo R, Torres-Fernandez D, Ballesteros A,

Viral Suppression, Viral Failure, and Safety Outcomes in Children and Adolescents With Human Immunodeficiency Virus (HIV) on Dolutegravir in Europe and Thailand

2025

Authors: Scott K, O’Rourke J, Jackson C, Ene L, Galli L, Goetghebuer T, Henegar C, Königs C, Marczyńska M, Naver L, Noguera-Julian A, Paioni P, Ramos JT,

Are children and adolescents living with HIV in Europe and South Africa at higher risk of SARS-CoV-2 and poor COVID-19 outcomes?

2025

Authors: European Pregnancy and Paediatric Infections Cohort Collaboration (EPPICC) SARS-CoV-2 Antibody Study Group

Published in: Epidemiology and Infections

Outcomes After Prenatal Exposure to Raltegravir-Containing Antiretroviral Therapy: A Multicohort European Study

2025

Authors: Sconza R, Fernandes G, Bailey H, Peters H, Prieto Tato LM, Illán Ramos M, Aebi-Popp K, Kahlert C, Gamell AM, Frick A, Ene L, Samarina A,

Effect of Empirical Treatment with Valganciclovir on Mortality in Infants with Severe HIV -associated Pneumonia: a multicenter, open-label, randomized factorial clinical trial

2025

Authors: C. Moraleda, A. Tagarro, S. Domínguez-Rodríguez, W.C. Buck, V. Musiime, H. Mujuru, C. Chabala, P.-Y. Iroh-Tam, T. Mvalo, J. Bramugy, L. Madrid, J. Sacarlal, A. Passanduca,

Effectiveness and safety of dolutegravir (DTG) in infants and children aged under 12-years at start of DTG in Europe and Thailand

2025

Authors: Scott K, Castro H, O’Rourke J, Edgar K, Ene L, Galli L, Goetghebuer T, Henegar C, Hoffmann UT, Königs C, Marczyńska M, Naver L, Noguera-Julian A,

Empirical treatment against tuberculosis in infants with HIV-associated pneumonia: a multicenter, open label, randomized factorial clinical trial.

2025

Authors: Tagarro A, Moraleda1 C, Dominguez-Rodríguez S, Buck C, Musiime V, Mujuru H,  Chabala C, Iroh Tam YP, Mvalo T, Bramugy J, Madrid L, Sacarlal J, Passanduca A,

Pharmacokinetic modeling to support WHO-weight band dosing of the new pediatric Darunavir/ritonavir (120/20 mg) fixed-dose combination tablet for children

2025

Authors: Abdalla S, Lallemant M, Compagnucci A, Nardone A, Giaquinto C, Gibb D, Chabala C, Burger D, Hirt D, Cressey RT for the UNIVERSAl-2 Team

Presented at: IAS 2025

Challenges of recruiting children living with HIV failing antiretroviral therapy into a trial for participants with multi-class drug resistance into a prospective clinical trial

2025

Authors: Grasa C, Archary M, Frigati L, Violari A, Patel F, Strehlau R, Camacho-Gonzalex A, Maboa R, Rakhmanina N, Salvadori N, Nardone A, Than-In-At K,Koblansky A, Thakka N,

Characteristics of antiretroviral resistance in participants from the SHIELD trial: a pharmacokinetic and safety study evaluating fostemsavir in children and adolescents living with multi-drug resistant HIV

2025

Authors: Archary M, Frigati L, Violari A, Patel F, Strehlau R, Camacho-Gonzalez A, Maboa R , Rakhmanina N, Grasa C, Salvadori N, Nardone A, Than-In-At K, Parry C, Keegan M,

Efficacy of second-line dolutegravir- versus boosted protease inhibitor-based ART in children and adolescents living with HIV at 96 and 144 weeks: pooled analysis of the ODYSSEY and CHAPAS-4 trials

2025

Presented by: Amuge P on behalf of the CHAPAS-4 trial, ODYSSEY trial and UNIVERSAL teams

Presented at: International Workshop on HIV and Pediatrics

Factors associated with HIV-1 DNA dynamics in early treated childrenwith perinatal HIV

2025

Presented by: Tagarro A, Reddy K, Molechan C, Dominguez-Rodriguez S, Smith T, Spyer M, Barnabas S, Lain M, Otwombe K, Nhampossa T, Maiga A, Rojo P, Giaquinto C,

Switching off dolutegravir in pregnancy during the safety signal period: a multi-cohort European study

2025

Authors: Fernandes G, Chappell E, Sconza R, Bailey H, Dalla Valle G, Aebi-Popp K, Ene L, Floridia M, Gamell A, Illán Ramos M, Peters H, Samarina A, Bamford A,

Switching off dolutegravir in pregnancy during the safety signal period: a multi-cohort European study

2025

Authors: Fernandes G, Chappell E, Sconza R, Bailey H, Valle DG, Aebi-Popp K, Ene L, Floridia M, Gamell A, Ramos IM ,

Brain MRI and neurocognitive characteristics of children and adolescents living with HIV

2025

Authors: Martín-Bejarano García M, Jackson C, Okhonskaia L, Voronin E, Rozenberg V, Titova MA, Kovalenko T, Wedderburn C, Collins IJ, Crichton S, Velo Higueras C, Salvador E,

EVOLUTION OF THE RESERVOIR IN EARLY TREATED CHILDREN WITH HIV-1 IN SUB-SAHARAN AFRICA

2025

Authors: Tagarro A, Reddy K, Barnabas S, Dominguez-Rodriguez S, Lain MG, Rojo P, Palma P, Ndung’u T, Spyer M, Nhampossa T, Otwombe K, Maiga A, Giaquinto C,

1 out of 20 children with HIV can achieve undetectable HIV-1 reservoir in Africa

2025

Authors: Tagarro A, Reddy K, Dominguez S, Barnabas S, Rojo P, Lain MG, Palma P, Cotugno N, Nastuoli E, Giaquinto C, N’Dungu T, Rossi P, on behalf of the EPIICAL Consortium

Presented at: ESPID 2025

View presentation slides

Statistical analysis plan for the “empirical treatment against cytomegalovirus and tuberculosis in HIV-infected infants with severe pneumonia” clinical trial

2025

Authors: Domínguez-Rodríguez S, Lora D, Tagarro A, Moraleda C, Ballesteros Á, Madrid L, Manukyan L, Marcy O, Leroy V, Nardone A, Burger D, Bassat Q, Bates M, Moh R,

Assessment of the steady-state drug-drug interactions between dolutegravir and ritonavir-boosted darunavir in adolescents

2025

Authors: Abdalla S, Compagnucci A, Bamford A, Chan MK, Ramos JT, Riault Y, Saidi Y, Constant V, Nguyen T, Giaquinto C, Tréluyer JM, Cressey TR, Hirt D, the SMILE Study Group,

Viral suppression, viral failure and safety outcomes in children and adolescents living with HIV on dolutegravir in Europe and Thailand 

2025

Authors: Scott K, O’Rourke J, Jackson C, Ene L, Galli L, Goetghebuer T, Henegar C, Königs C, Marczyńska M, Naver L, Noguera-Julian A, Paioni P, Ramos JT,

Penta Network: State-of-the-Art Research in Pediatric Human Immunodeficiency Virus

2025

Authors: Rojo P, Moraleda C, Giaquinto C

Published in: Clinics in Perinatology

Infants with HIV starting ART withing 4 months of age can achieve sustained undetectable HIV-1 DNA

2025

Authors: Tagarro A, Reddy K, Dominguez-Rodriguez S, Rojo P, Barnabas S, Otwombe K, Lain MG, Maiga A, Kuhn L, Palma P, Cotugno N, Nastuoli E, Giaquinto C,

Virological outcomes and genotypic resistance on dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial

2025

Authors: White E, Kityo C, Spyer MJ, Mujuru HA, Nankya I, Kekitiinwa AR, Lugemwa A, Kaudha E, Liberty A, Cassim H, Archary M, Cotton MF, Ahimbisibwe GM, Cressey TR,

Long-term non-progression in children living with HIV: estimates from international cohort data.

2025

Authors: Jackson C, Crichton S, Judd A, Bamford A, Goulder P, Klein N, Marques L, Paioni P, Riordan A, Spoulou V, Vieira VA, Ansone S, Chiappini E,

Genetic variation on dolutegravir pharmacokinetics and relation to safety and efficacy outcomes: a systematic review

2025

Authors: Bevers LAH, Jensen RL, Owen A, Colbers A, Carr DF, Burger DM

Published in: Pharmacogenomics

Perinatal HIV: Past, Present, and Future

2024

Editors: Violari A, Chahroudi A

Published in: Clinics in Perinatology

Sharing Data and Transferring Samples Within Pediatric Clinical Studies: How to Overcome Challenges and Make Them a Science Opportunity

2024

Authors: Landi A, D’Ambrosio F, Faggion S, Rocchi F, Paganin C, Lain MG, Ceci A, Giannuzzi V on behalf of the EPIICAL Consortium

Published in: Healthcare

Outcomes following prenatal exposure to DTG-containing antiretroviral therapy regimens: data from the DOLOMITE-EPPICC study

2024

Authors: Sconza R, Fernandes G, Bailey H, Aebi-Popp K, Ene L, Floridia M, Gamell MA, Ramos IM, Peters H, Samarina A, Ragone L, Vannappagari V,Thorne C for Dolomite-EPPICC Study Group

Presented at: Glasgow HIV

View poster

Early inflammation as a footprint of increased mortality risk in infants living with HIV from three African countries

2024

Authors: Morrocchi E, Pascucci GR, Cotugno N, Pighi C, Dominguez-Rodriguez S, Petrara MR, Tagarro A, Kuhn L, Cotton MF, Otwombe K, Lain MG, Vaz P, Barnabas SL, Spyer MJ,

HIV postnatal prophylaxis and infant feeding policies vary across Europe: results of a Penta survey

2024

Authors: Fernandes G, Chappell E, Goetghebuer T, Kahlert CR, Ansone S, Bernardi S, Castelli Gattinara G, Chiappini E, Dollfus C, Frange P, Freyne B, Galli L, Giacomet V,

Optimising Paediatric HIV Treatment: Recent Developments and Future Directions

2024

Authors: Kamphuis A.E.M., Bamford A., Tagarro A.,  Cressey AT, Bekker A, Amuge P, Mujuru HA, Ndongo AF, Diack A, Compagnucci A, Lallemant M, Colbers A, Turkova A.

HIV reservoir and premature aging: risk factors for aging-associated illnesses in adolescents and young adults with perinatally acquired HIV

2024

Authors: Petrara MR, Ruffoni E, Carmona F, Cavallari I, Zampieri S, Morello M, Del Bianco P, Rampon O, Cotugno N, Palma P, Rossi P, Giaquinto C, Giunco S,

Diagnosis of tuberculosis infection in children with a novel skin test and the traditional tuberculin skin test: An observational study

2024

Authors: Fritschi N, Gureva T, Eliseev P, Jackson C, Milanzi E, Crichton S, Collins IJ, Turkova A, Mariandyshev A, Ritz N.

Published in: Plos One

Viral suppression, viral failure and safety outcomes in children and adolescents on​dolutegravir (DTG) in Europe and Thailand

2024

Authors: Scott K, Crichton S, O’Rourke J, Chappell E, Ene L, Galli L, Goetghebuer T, Henegar C, Hoffmann T,  Königs C, Magdalena Marczyńska M,  Naver L,  Noguera-Julian A, 

Read More

Changes in body mass index before and after starting dolutegravir and compared to protease inhibitors in children and adolescents living with HIV in Europe and Thailand

2024

Authors: Crichton S, Edgar K, Scott K, Chappell E, Álvarez B, Ene L, Galli L, Goetghebuer T, Henegar C, Hoffmann UT, Kahlert C, Königs C, Marczyńska M, Naver L,

Read More

Analytical treatment interruption in children living with HIV: position statement from the EPIICAL consortium

2024

Authors: Kuhn L, Barnabas S, Cotugno N, Peay H, Goulder P, Cotton M, Violari A, Pahwa S, Reddy K, Tagarro A, Otwombe K, Fry S, Vaz P,

Effectiveness and Safety of Dolutegravir in Children and Adolescents Living With HIV in Europe and Thailand

2024

Authors: Scott K, O’Rourke J, Crichton S, Chappell E, Ene L, Galli L, Goetghebuer T, Henegar C, Hoffmann UT, Königs C, Marczyńska M, Naver L, Noguera-Julian A,

Read More

Viral failure in children and adolescents living with HIV on dolutegravir (DTG) in Europe and Thailand

2024

Authors: Scott K, Crichton S, Jackson C, Ene L, Galli L, Goetghebuer T, Henegar C, Königs C, Marczyńska M, Naver L, Noguera-Julian A, Paioni P, Puthanakit T, Ramos TJ, Smith B,

Read More

D3/Penta 21 clinical trial design: A randomised non-inferiority trial with nested drug licensing substudy to assess dolutegravir and lamivudine fixed dose formulations for the maintenance of virological suppression in children with HIV-1 infection, aged 2 to 15 years

2024

Authors: Turkova A, Chan MK, Kityo C, Kekitiinwa AR, Musoke P, Violari A, Variava E, Archary M, Cressey TR, Chalermpantmetagul S, Sawasdichai K, Ounchanum P, Kanjanavanit S,

HIV-1 drug resistance dynamics in the EARTH cohort: a mother-infant pair perspective

2024

Authors: Torres-Fernandez D, Domínguez-Rodríguez S, Fernández-Luis S, Nhampossa T, Lopez-Varela E, Naniche D, Lain GM, Ismael N, Spyer JM, Byott M, Nastouli E, Rossi P, Rojo P, Tagarro A on behalf of the EPIICAL Consortium.

Read More

HIV-1 drug resistance dynamics in the EARTH cohort: a mother-infant pair perspective

2024

Authors: Torres-Fernandez D, Domínguez-Rodríguez S, Fernández-Luis S, Nhampossa T, Lopez-Varela E, Naniche D, Lain GM, Ismael N, Spyer JM, Byott M, Nastouli E, Rossi P, Rojo P, Tagarro A on behalf of the EPIICAL Consortium.

Read More

High mortality following early initiation of antiretroviral therapy in infants living with HIV from three African countries

2024

Authors: Tagarro A, Domínguez-Rodríguez S, Cotton M, Otwombe K, Klein N, Lain GM, Nhampossa T, Maiga IA, Barnabas S, Vaz P, Violari A, Fernández-Luis S, Behuhuma O,

Pharmacokinetics of once-daily DTG/3TC FDC in children living with HIV: D3/PENTA21 sub-study

2024

Authors: Bevers HAL, Chan KM, Bbuye D, Kekitiinwa RA, Kityo C, Kaudha E, Ahimbisibwe MG, Arumugam T, Moloantoa T, Boles J, Deprez I, Giaquinto C, Turkova A, Colbers A for the D3/Penta21 trial team

Presented at: CROI 2024

Read more

HIV-1 Reservoir Dynamics in Children With Early Treated, Perinatally-Acquired HIV: Does Sex Matter?

2024

Authors: Reddy K, Molechan C, Dominguez-Rodriguez S, Smith T, Spyer M, Lichterfeld M, Rojo P, Giaquinto C, Rossi P, Palma P, Isaacs M, Cardoso L, Liberty A, Estevao L,

Read more

Outcomes Following Prenatal Exposure to Raltegravir: A Multi-Cohort European Study

2024

Authors: Sconza R, Fernandes G, Aebi-Popp K, Ene L, Frick A, Gamell A, Ramos IM, Kahlert C, Peters H, Tato PML, Samarina A, Giaquinto C, Thorne C for the EPPICC Pregnancy Study Group

Presented at: CROI 2024

Read More

ODYSSEY 192-week follow-up evidences superior efficacy of DTG for children on first/second-line ART

2024

Authors: Mujuru AH, White E, Kekitiinwa A, Lugemwa A, Kityo C, Musoke P, Cressey RT, Variava E, Violari A, Archery M, Cotton M, Puthanakit T, Rojo P, Turkova A

Presented at: CROI 2024

Read More

Causes of death after early ART in infants living with HIV from 3 sub-Saharan African countries

2024

Authors: Tagarro A, Fernández-Luis S, Dominguez-Rodriguez S, Ballesteros A, Kuhn L, Cotton FM, Giaquinto C, Rossi P, Spyer M, Otwombe K, Behuhuma O, Vaz P, Foster C, Rojo P,

Read More

An efficient envelope genotypic assay to identify bNab susceptibility in infants with HIV

2024

Authors: Delaney EK, Kearney FM, Bester AP, Coetzee N, Engelbrecht S, Giaquinto C, Rossi P, Barnabas LS, Spyer JM, Litcherfeld M, Tagarro A, Lombard C, Cotton FM, Zyl vUG and EPIICAL Consortium

Presented at: CROI 2024

Read More

1 in 5 sub-Saharan infants switches from undetectable to detectable HIV viral load during follow-up  

2024

Authors: Fernández-Luis S, Dominguez-Rodriguez S, Kuhn L, Cotton M, Giaquinto C, Rossi P, Rensburg JVA, Violari A, Lain GM, Lopez-Varela E, Sylla M, Amugue P, Rojo P, Tagarro A for EPIICAL Consortium

Presented at: CROI 2024

Read More

Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023

2024

Authors: Ambrosioni J, Levi L, Alagaratnam J, Van Bremen K, Mastrangelo A, Waalewijn H, Molina JM, Guaraldi G, Winston A, Boesecke C, Cinque P, Bamford A, Calmy A,

123456789